Search

Your search keyword '"Moritz Fürstenau"' showing total 9 results
Start Over Author "Moritz Fürstenau" Publisher wiley
9 results on '"Moritz Fürstenau"'

1. S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL

Author

Petra Langerbeins, Sandra Robrecht, Pascal Nieper, Paula Cramer, Moritz Fürstenau, Othman Al-Sawaf, Anna-Maria Fink, Karl-Anton Kreuzer, Ursula Vehling-Kaiser, Eugen Tausch, Christof Schneider, Lothar Müller, Michael Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Clemens Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, and Michael Hallek

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

2. P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL

Author

Florian Simon, Rudy Ligtvoet, Thomas Noesslinger, Jan-Paul Bohn, Julia Von Tresckow, Rüdiger Liersch, Tobias Gaska, Kathleen Jentsch-Ullrich, Michael Koenigsmann, Thomas Wolff, Ingo Schwaner, Dominik Wolf, Christof Schneider, Eugen Tausch, Stephan Stilgenbauer, Karl-Anton Kreuzer, Sandra Robrecht, Anna-Maria Fink, Moritz Fürstenau, Kirsten Fischer, Valentin Goede, Michael Hallek, and Barbara Eichhorst

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

4. Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?

Author

Moritz Fürstenau, Nisha De Silva, Barbara Eichhorst, and Michael Hallek

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Abstract. The introduction of chemoimmunotherapy and more recently the implementation of novel agents into first-line and relapse treatment have substantially improved treatment outcomes in patients with chronic lymphocytic leukaemia (CLL). With longer progression-free survival and more frequently observed deep remissions there is an emerging need for sensitive methods quantitating residual disease after therapy. Over the last decade, assessment of minimal residual disease (MRD) has increasingly been implemented in CLL trials. The predictive value of MRD status on survival outcomes has repeatedly been proven in the context of chemoimmunotherapy and cellular therapies. Recent data suggests a similar correlation for Bcl-2 inhibitor-based therapy. While the relevance of MRD assessment as a surrogate endpoint in clinical trials is largely undisputed, its role in routine clinical practice has not yet been well defined. This review outlines current methods of MRD detection in CLL and summarizes MRD data from relevant trials. The significance of MRD testing in clinical studies and in routine patient care is assessed and new MRD-guided treatment strategies are discussed.

Published
2019
Full Text
View/download PDF

5. Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia

Author

Steffen Dörfel, Ulrich Kaiser, Hanns-Detlev Harich, Christian Maurer, Kirsten Fischer, Hartmut Linde, Thomas Stumpf, Barbara Eichhorst, Moritz Fürstenau, Sandra Robrecht, Lutz Jacobasch, Adam Giza, Michael Koenigsmann, Ali Aldaoud, Anna-Maria Fink, Julia Von Tresckow, Tobias Gaska, and Michael Hallek

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Chronic lymphocytic leukemia, Medizin, MEDLINE, Antineoplastic Agents, Young Adult, Text mining, Internal medicine, medicine, Humans, Prospective Studies, Aged, Aged, 80 and over, business.industry, Incidence, Neoplasms, Second Primary, Hematology, Second primary cancer, Middle Aged, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Female, business
Abstract

in press

Published
2021
Full Text
View/download PDF

6. How to approach CLL in clinical practice

Author

Michael Hallek and Moritz Fürstenau

Subjects
Cancer Research, medicine.medical_specialty, business.industry, MEDLINE, Hematology, General Medicine, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Clinical Practice, Leukemia, Text mining, Oncology, medicine, Humans, Intensive care medicine, business
Published
2019
Full Text
View/download PDF

7. BENDAMUSTINE, FOLLOWED BY OBINUTUZUMAB, ACALABRUTINIB AND VENETOCLAX IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAAG TRIAL OF THE GCLLSG

Author

M Brüggemann, Michael Kneba, S. Stilgenbauer, Sebastian Böttcher, Petra Langerbeins, Barbara Eichhorst, Moritz Fürstenau, C M Wendtner, J. Schetelig, Karl-Anton Kreuzer, A. M. Fink, Christof Schneider, Kirsten Fischer, O. Al Sawaf, Adam Giza, Peter Dreger, Michael Hallek, Sandra Robrecht, Paula Cramer, Eugen Tausch, and A. Schilhabel

Subjects
Bendamustine, Oncology, Cancer Research, medicine.medical_specialty, Venetoclax, business.industry, Chronic lymphocytic leukemia, Hematology, General Medicine, medicine.disease, chemistry.chemical_compound, chemistry, Obinutuzumab, Internal medicine, Relapsed refractory, medicine, Acalabrutinib, In patient, business, medicine.drug
Published
2021
Full Text
View/download PDF

8. COVID‐19 complicated by parainfluenza co‐infection in a patient with chronic lymphocytic leukemia

Author

Jan Rybniker, Henning Gruell, Moritz Fürstenau, B. Böll, Philipp Koehler, Michael Hallek, P. Langerbeins, Tamina Seeger-Nukpezah, M. Kochanek, Barbara Eichhorst, Thorsten Persigehl, and Florian Klein

Subjects
Male, Coronavirus disease 2019 (COVID-19), Chronic lymphocytic leukemia, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), viruses, Case Report, Case Reports, medicine.disease_cause, Antibodies, Viral, 03 medical and health sciences, 0302 clinical medicine, COVID‐19, medicine, Humans, Respiratory system, IgG Deficiency, Pandemics, Immunodeficiency, Coronavirus, Paramyxoviridae Infections, business.industry, Coinfection, SARS-CoV-2, fungi, virus diseases, COVID-19, Immunoglobulins, Intravenous, Hematology, General Medicine, biochemical phenomena, metabolism, and nutrition, Middle Aged, medicine.disease, Virology, Leukemia, Lymphocytic, Chronic, B-Cell, respiratory tract diseases, 030220 oncology & carcinogenesis, Superinfection, Spike Glycoprotein, Coronavirus, chronic lymphocytic leukemia, business, immunodeficiency, 030215 immunology, Co infection
Abstract

The number of people suffering from the new coronavirus SARS‐CoV‐2 continues to rise. In SARS‐CoV‐2, superinfection with bacteria or fungi seems to be associated with increased mortality. The role of co‐infections with respiratory viral pathogens has not yet been clarified. Here, we report the course of COVID‐19 in a CLL patient with secondary immunodeficiency and viral co‐infection with parainfluenza.

Published
2020
Full Text
View/download PDF

9. IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE-BLIND RANDOMIZED CLL12 TRIAL

Author

Othman Al-Sawaf, Barbara Eichhorst, A. M. Fink, P. Cramer, C. Rhein, Jasmin Bahlo, Eugen Tausch, H. Gerwin, Werner Freier, Stephan Stilgenbauer, P. Langerbeins, M. Reiser, Lutz P. Müller, J. von Tresckow, Martina Stauch, Ursula Vehling-Kaiser, Tobias Gaska, Christina Balser, Michael J. Eckart, Michael Hallek, Kirsten Fischer, Moritz Fürstenau, Clemens-Martin Wendtner, Rudolf Schlag, and Karl-Anton Kreuzer

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, Placebo, Gastroenterology, Asymptomatic, Double blind, Therapy naive, chemistry.chemical_compound, Oncology, chemistry, Internal medicine, Ibrutinib, Clinical endpoint, Medicine, In patient, Stage (cooking), medicine.symptom, business
Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results